Percentages in chart are as a percent to total sales) Fiscal Nine months Q 3 2022 versus Fiscal Nine months Q 3 2021 Cost of products sold increased as a percent to sales driven by: • Commodity inflation in the MedTech and Consumer Health segments • Currency in the Pharmaceutical segmentpartially offset by • Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical segment • Supply chain benefits in the MedTech and Consumer Health segmentsThe intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2022 and 2021 was $3.2 billion and $3.6 billion, respectively.Sales by international companies were $11.3 billion, a total decrease of 0.3%, which included operational growth of 12.3% offset by a negative currency impact of 12.6%.International MedTech sales decreased by 0.1%, including an operational increase of 8.2% offset by a negative currency impact of 8.3%.The latest expiring United States composition of matter patent for STELARA (ustekinumab) will expire in September 2023.The decline in sales of INVOKANA/INVOKAMET (canagliflozin) were due to continued share erosion.Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company’ s key pharmaceutical products prior to expiration of the applicable patents covering those products.Sales by U. S. companies were $36.1 billion in the fiscal nine months of 2022, which represented an increase of 3.1% as compared to the prior year.Sales by U. S. companies were $12.5 billion in the fiscal third quarter of 2022, which represented an increase of 4.1% as compared to the prior year.The updated policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company’ s drugs, subject to multiple exceptions.The 340B Drug Pricing Program is a U. S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS.The Company’ s debt position was $32.0 billion as of October 2, 2022 as compared to $33.9 billion the same period a year ago.The Company has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites have been involved in the production of the vaccine across different countries and continents.